Your browser doesn't support javascript.
Infectious Period of Severe Acute Respiratory Syndrome Coronavirus 2 in 17 Nursing Home Residents-Arkansas, June-August 2020.
Surie, Diya; Huang, Jennifer Y; Brown, Allison C; Gable, Paige; Biedron, Caitlin; Gilbert, Sarah E; Garner, Kelley; Bollinger, Susan; Gulley, Trent; Haney, Tafarra; Lyons, Amanda K; Beshearse, Elizabeth; Gregory, Christopher J; Sabour, Sarah; Clemmons, Nakia S; James, Allison E; Tamin, Azaibi; Reese, Natashia; Perry-Dow, K Allison; Brown, Robin; Harcourt, Jennifer L; Campbell, Davina; Houston, Hollis; Chakravorty, Rohan; Paulick, Ashley; Whitaker, Brett; Murdoch, Jordan; Spicer, Lori; Stumpf, Megan M; Mills, Lisa; Coughlin, Melissa M; Higdem, Pamela; Rasheed, Mohammad Ata Ur; Lonsway, David; Bhatnagar, Amelia; Kothari, Atul; Anderson, Karen; Thornburg, Natalie J; Breaker, Erin; Adamczyk, Michelle; McAllister, Gillian A; Halpin, Alison L; Seely, Kathryn A; Patil, Naveen; McDonald, L Clifford; Kutty, Preeta K.
  • Surie D; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Huang JY; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Brown AC; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gable P; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Biedron C; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gilbert SE; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Garner K; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Bollinger S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gulley T; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Haney T; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Lyons AK; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Beshearse E; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gregory CJ; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Sabour S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Clemmons NS; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • James AE; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Tamin A; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Reese N; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Perry-Dow KA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Brown R; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Harcourt JL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Campbell D; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Houston H; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Chakravorty R; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Paulick A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Whitaker B; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Murdoch J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Spicer L; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Stumpf MM; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Mills L; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Coughlin MM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Higdem P; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rasheed MAU; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Lonsway D; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Bhatnagar A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kothari A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Anderson K; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Thornburg NJ; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Breaker E; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Adamczyk M; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • McAllister GA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Halpin AL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Seely KA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Patil N; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • McDonald LC; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Kutty PK; Arkansas Department of Health, Little Rock, Arkansas, USA.
Open Forum Infect Dis ; 8(3): ofab048, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1135878
ABSTRACT

BACKGROUND:

To estimate the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adults with underlying conditions, we assessed duration of coronavirus disease 2019 (COVID-19) symptoms, reverse-transcription polymerase chain reaction (RT-PCR) positivity, and culture positivity among nursing home residents.

METHODS:

We enrolled residents within 15 days of their first positive SARS-CoV-2 test (diagnosis) at an Arkansas facility from July 7 to 15, 2020 and instead them for 42 days. Every 3 days for 21 days and then weekly, we assessed COVID-19 symptoms, collected specimens (oropharyngeal, anterior nares, and saliva), and reviewed medical charts. Blood for serology was collected on days 0, 6, 12, 21, and 42. Infectivity was defined by positive culture. Duration of culture positivity was compared with duration of COVID-19 symptoms and RT-PCR positivity. Data were summarized using measures of central tendency, frequencies, and proportions.

RESULTS:

We enrolled 17 of 39 (44%) eligible residents. Median participant age was 82 years (range, 58-97 years). All had ≥3 underlying conditions. Median duration of RT-PCR positivity was 22 days (interquartile range [IQR], 8-31 days) from diagnosis; median duration of symptoms was 42 days (IQR, 28-49 days). Of 9 (53%) participants with any culture-positive specimens, 1 (11%) severely immunocompromised participant remained culture-positive 19 days from diagnosis; 8 of 9 (89%) were culture-positive ≤8 days from diagnosis. Seroconversion occurred in 12 of 12 (100%) surviving participants with ≥1 blood specimen; all participants were culture-negative before seroconversion.

CONCLUSIONS:

Duration of infectivity was considerably shorter than duration of symptoms and RT-PCR positivity. Severe immunocompromise may prolong SARS-CoV-2 infectivity. Seroconversion indicated noninfectivity in this cohort.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Open Forum Infect Dis Year: 2021 Document Type: Article Affiliation country: Ofid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Open Forum Infect Dis Year: 2021 Document Type: Article Affiliation country: Ofid